Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyPsyence Group2025-04-21T08:16:12+02:00April 21, 2025|Read More
Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply AgreementPsyence Group2025-04-15T14:50:08+02:00April 15, 2025|Read More
Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in AustraliaPsyence Group2025-04-09T09:40:45+02:00April 9, 2025|Read More
Psyence Biomedical LTD Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable ManufacturingPsyence Group2025-03-31T14:48:31+02:00March 31, 2025|Read More
Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. SteinPsyence Group2025-03-19T14:36:13+02:00March 19, 2025|Read More
Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory BoardPsyence Group2025-02-28T03:17:53+02:00February 28, 2025|Read More
Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing RequirementsPsyence Group2024-12-24T09:24:57+02:00December 23, 2024|Read More
Psyence Biomed Announces $2.0 Million Private PlacementPsyence Group2024-12-24T09:36:59+02:00December 23, 2024|Read More
